Citius Pharmaceuticals, Inc.,"Citius" (OTCQB: CTXR) today announced that the Company has completed the final phase of its private placement offering of 7.6mm units for net proceeds of $4.1mm dollars. Each unit consists of one share of common stock and one warrant to purchase a share of common stock for $0.60 per share. As a result of the completion of this offering, the Company now maintains 73 million common voting shares outstanding. Citius intends to use the proceeds of this offering for product development and general working capital purposes.
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical
company dedicated to the development and commercialization of critical
care products with primary focus on anti-infectives and adjunctive
cancer-care drug products using innovative, patented or proprietary
formulations of previously approved pharmaceuticals. We seek to achieve
leading market positions by providing therapeutic products that address
unmet medical needs. By using previously approved drugs with substantial
safety and efficacy data, we seek to reduce the risks associated with
pharmaceutical product development and regulatory requirements. We focus
on developing products that have intellectual property protection and
competitive advantages to existing therapeutic approaches.
No comments:
Post a Comment